Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aeglea Biothera (NQ: AGLE )

7.790 USD UNCHANGED
Streaming Delayed Price Updated: 7:39 PM EST, Mar 1, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 7.790
Bid (Size) 6.300 (2)
Ask (Size) 8.040 (11)
Prev. Close 7.790
Today's Range 7.790 - 7.790
52wk Range 3.500 - 11.38
Shares Outstanding 21,858,874
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today... 
From PR Newswire
Aeglea BioTherapeutics Announces Transition of Chief Financial Officer
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today... 
From PR Newswire

Performance

YTD
-9.00%
-9.00%
1 Month
+6.86%
+6.86%
3 Month
-9.00%
-9.00%
6 Month
+7.08%
+7.08%
1 Year
+13.23%
+13.23%

More News

Read More
Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
From PR Newswire
Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors
From PR Newswire
Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria
From PR Newswire
Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference
From PR Newswire
Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences
From PR Newswire
Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights
From PR Newswire
Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria
From PR Newswire
Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings
From PR Newswire
Aeglea BioTherapeutics to Participate in September Investment Conferences
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.